Effect of anti-viral therapy for occult hepatitis C virus infection

Aliment Pharmacol Ther. 2006 Apr 15;23(8):1153-9. doi: 10.1111/j.1365-2036.2006.02886.x.

Abstract

Background: Occult hepatitis C virus infection is defined by the presence of hepatitis C virus-RNA in liver but with undetectable anti-hepatitis C virus and serum viral RNA.

Aim: To study the response to anti-viral therapy in occult hepatitis C virus infection to assess the pathogenic effect of occult hepatitis C virus.

Methods: Ten patients with occult hepatitis C virus infection were treated with pegylated-interferon plus ribavirin for 24 weeks and were followed-up 24 weeks after therapy. All patients had abnormal alanine aminotransferase, hepatitis C virus-RNA positive in peripheral blood mononuclear cells and liver necroinflammation.

Results: At the end of treatment and follow-up, the percentage of patients with normal alanine aminotransferase was 80% (95% CI: 48-96%) and 60% (95% CI: 31-84%) respectively, and hepatitis C virus-RNA in peripheral blood mononuclear cells was negative in 80% (95% CI: 48-96%) and 70% (95% CI: 40-90%) cases. At the end of follow-up sustained response was observed in 30% (95% CI: 11-61%) of cases. Five patients underwent a second liver biopsy. In all cases, liver hepatitis C virus-RNA persisted, although hepatitis C virus-RNA load was significantly lower (3.2 x 10(4) +/- 5.1 x 10(4) copies/microg RNA) than in the basal biopsy (2.4 x 10(5) +/- 3.8 x 10(5) copies/microg RNA); (P = 0.043). Necroinflammation and fibrosis decreased in three cases.

Conclusion: The biochemical, virological and histological response to therapy achieved in patients with occult hepatitis C virus infection demonstrates the pathologic effects of occult hepatitis C virus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Alanine Transaminase / blood
  • Antiviral Agents / therapeutic use*
  • Confidence Intervals
  • Female
  • Follow-Up Studies
  • Hepacivirus* / genetics
  • Hepacivirus* / pathogenicity
  • Hepatitis C / drug therapy*
  • Hepatitis C / enzymology
  • Hepatitis C / virology
  • Humans
  • In Situ Hybridization / methods
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use*
  • Leukocytes, Mononuclear / virology
  • Liver / pathology
  • Liver / virology*
  • Liver Cirrhosis / enzymology
  • Liver Cirrhosis / virology
  • Male
  • Middle Aged
  • Polyethylene Glycols / therapeutic use*
  • RNA, Viral / analysis
  • Recombinant Proteins
  • Ribavirin / therapeutic use*
  • Statistics, Nonparametric
  • Viral Load

Substances

  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • RNA, Viral
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • Alanine Transaminase
  • peginterferon alfa-2a